Earlier studies showed that inhibition of COX-2 (by NS-398) along with epidermal growth factor receptor (EGFR) (through gefitinib) resulted in increased cytotoxicity of Docetaxel along with reduced cancer cell migration [32]. This evidence concerns the gene EGFR and cancer.